Approximate Dose Equivalency of Statin LDL-C Efficacy

Residual CV Risk

Approaches to Reducing Residual Risk

IMPROVE-IT Efficacy

IMPROVE-IT Safety

ODYSSEY Long-Term Time to First Adjudicated Major CV Event

Safety of Intensive LDL-C Lowering

ODYSSEY HIGH FH

ODYSSEY ALTERNATIVE: PCSK9 in Statin-Intolerant Patients Study Design

Alirocumab Significantly Reduced LDL-C in Statin-Intolerant Patients

Incidence of Muscle AEs on Statin Therapy

LDL-C Lowering Cognitive Impairment

Combination Therapy

PCSK9 Mutations

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)